Forma Medical Launches OptimalHT, the World’s First Minimally Invasive Instrumented Hammertoe Arthrodesis Procedure, Completes 50+ Procedures

Forma Medical, an emerging innovator in medical device technologies, announces today the launch of OptimalHT, the world’s first instrumented Minimally Invasive Surgery (MIS) Hammertoe Arthrodesis procedure. OptimalHT received FDA approval in July as the company’s inaugural product launch and has treated more than 50 hammertoe deformities.

“It’s no secret that minimally invasive surgery is the future of foot and ankle care,” said Dr. Noman Siddiqui, DPM, LifeBridge Health, Baltimore. “The novel OptimalHT approach for digital correction is ideal for less invasive surgery in the foot to reduce edema, expedite recovery, and achieve the results my patients demand.”

Less invasive than other hammertoe-specific products on the market, OptimalHT is a uniquely instrumented procedure designed to provide repeatable outcomes with minimal incisions. It is also more cost effective and scalable than other attempts at hammertoe-specific products.

“Receiving our first FDA approval and launching the OptimalHT system represents a pivotal moment for Forma Medical,” said James Gault, Vice President of Forma Medical. “With this FDA approval, we now have a platform to launch life-changing systems across multiple anatomies. We are continuing to push the envelope and expand our portfolio to advance patient care.”

According to the US Census Bureau, the country is seeing unprecedented growth in the active aging population. With the number of people experiencing painful hammertoe deformities at an all-time high, and expected to rise, the need to better meet patient expectations is imperative.

“Retrograde k-wire fixation has been an acceptable treatment for decades, yet I’ve recently come to appreciate that some patients are returning to my practice years later with recurrent toe deformities. When I give them the choice, they also seem to be less tolerant of the pins sticking out of the toe and more inclined to pursue a quicker return to standard footwear,” says Jesse Doty, MD, Erlanger Health System, Chattanooga. “With OptimalHT, it’s been seamless for me to incorporate the proven results of a k-wire or to take it a step further with more reliable fixation in a repeatable way that my patients find less inconvenient.”

Forma Medical will debut OptimalHT at the American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting in September. For more information about Forma Medical and to learn about the company’s groundbreaking technology, please visit or

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy